Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions

September 8, 2011 By Bio-Medicine.Org

HAYWARD, Calif., Sept. 8, 2011 /PRNewswire/ — Anthera
Pharmaceuticals, Inc. (Nasdaq:
ANTH
), a biopharmaceutical company developing drugs to treat
serious diseases associated with inflammation, today announced that
the U.S. Patent and Trademark Office has given the Company a Notice
of Allowance for U.S. Patent Application No. 12/114,710 entitled
“Treatment of cardiovascular disease and dyslipidemia using
secretory phospholipase A2 (sPLA2) inhibitors and sPLA2 inhibitor
combination therapies.” The patent grants Anthera exclusive rights
to compositions containing varespladib and any statins such as
Lipitor® (atorvastatin calcium) or Crestor®
(rosuvastatin calcium). Statin therapies are currently utilized to
manage high cholesterol levels in patients with various
cardiovascular diseases including Acute Coronary Syndrome (ACS). As
disclosed in the patent application, the combination of varespladib
with a statin demonstrated unexpected synergy for lowering LDL
levels and reducing atherosclerotic plaque formation. The U.S.
Patent and Trademark Office further notified the Company that
following issuance, the patent will receive a Patent Term
Adjustment of 353 days.

“This patent allowance provides another cornerstone to our
product life cycle planning for varespladib. In our current Phase 3
VISTA-16 clinical study, we are evaluating the potential of
varespladib methyl in combination with Lipitor to reduce the risk
of future heart attacks in high-risk patients with Acute Coronary
Syndrome,” said Paul F. Truex, Anthera’s President and Chief
Executive Officer. “The additional exclusivity period of this new
patent will provide Anthera added flexibility to maximize and
expand future development options for varespladib in combination
with statins – the largest class of marketed cardiovascular
therapeutics.”

About Varespladib and sPLA2

Varespladi

‘/>”/>

SOURCE

Related Articles Read More >

A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials

DeviceTalks Weekly.

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech